

1 **The impact of colectomy and chemotherapy on risk of type 2 diabetes onset in patients with**  
2 **colorectal cancer: Nationwide cohort study in Denmark**  
3

4 Caroline Elisabeth Krag<sup>1,2\*</sup>, Maria Saur Svane<sup>1,3\*</sup>, Sten Madsbad<sup>1</sup>, Susanne Boel Graversen<sup>8</sup>, Jesper  
5 Frank Christensen<sup>4,5,6</sup>, Thorkild IA Sørensen<sup>7</sup>, Louise Lang Lehrskov<sup>4\*</sup>, Tinne Laurberg<sup>8\*</sup>

6 *\*shared authors*  
7

8 **Affiliations**

9 <sup>1</sup> Department of Endocrinology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre,  
10 Denmark.

11 <sup>2</sup> Department of Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,  
12 2200 Copenhagen, Denmark.

13 <sup>3</sup> Department of Surgical Gastroenterology, Copenhagen University Hospital Hvidovre, 2650  
14 Hvidovre, Denmark

15 <sup>4</sup> Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet,  
16 Copenhagen, 2100 Copenhagen, Denmark.

17 <sup>5</sup> Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University  
18 of Southern Denmark, 5000 Odense, Denmark

19 <sup>6</sup> Digestive Disease Center, Bispebjerg Hospital, 2400 Copenhagen, Denmark

20 <sup>7</sup> Novo Nordisk Foundation Center for Basic Metabolic Research and Department of Public Health,  
21 University of Copenhagen, 2200 Copenhagen, Denmark.

22 <sup>8</sup> Steno Diabetes Center Aarhus, Aarhus University Hospital, 8200 Aarhus, Denmark.  
23

24 **Corresponding Author:**

25 Louise Lang Lehrskov, MD, PhD

26 The Centre for Physical Activity Research (CFAS),

27 Blegdamsvej 9,

28 DK-2100 Copenhagen, Denmark

29 Fax 45 35 45 76 44

30 Email: [louise.lang.lehrskov.01@regionh.dk](mailto:louise.lang.lehrskov.01@regionh.dk)

31 <http://aktivsundhed.dk>  
32

33 **Running title:** *KRAG et al: COLORECTAL CANCER TREATMENT AND ONSET OF TYPE 2*  
34 *DIABETES*  
35  
36

37 **Word count:** 3112

38 **Figures:** 2

39 **Tables:** 4  

---

40 **References:** 35

41 **Key words:** Colorectal cancer, surgery, chemotherapy, type 2 diabetes

42

43 **Impact statement:** Colon cancer treatment per se can affect type 2 diabetes risk, but bmi at time of  
44 surgery holds the strongest association.

45

46 **Abstract**

47 **Background**

48 Comorbidity with type 2 diabetes (T2D) results in worsening of cancer-specific and overall  
49 prognosis in colorectal cancer (CRC) patients. The treatment of CRC *per se* may be diabetogenic.

50 We assessed the impact of different types of surgical cancer resections and oncological treatment on  
51 risk of T2D development in CRC patients.

52 **Method**

53 We developed a population-based cohort study including all Danish CRC patients, who had  
54 undergone CRC surgery between 2001-2018. Using nationwide register data, we identified and  
55 followed patients from date of surgery and until new-onset of T2D, death or end of follow-up.

56 **Results**

57 In total, 46,373 CRC patients were included and divided into six groups according to type of  
58 surgical resection: 10,566 Right-No-Chemo (23%), 4,645 Right-Chemo (10%), 10,151 Left-No-  
59 Chemo (22%), 5,257 Left-Chemo (11%), 9,618 Rectal-No-Chemo (21%) and 6,136 Rectal-Chemo  
60 (13%). During 245,466 person-years of follow-up 2,556 patients developed T2D. The incidence  
61 rate (IR) of T2D was highest in the Left-Chemo group 11.3 (95%CI: 10.4-12.2) per 1,000 person-  
62 years and lowest in the Rectal-No-Chemo group 9.6 (95%CI: 8.8-10.4). Between-group unadjusted  
63 hazard ratio (HR) of developing T2D was similar and non-significant. In the adjusted analysis,  
64 Rectal-No-Chemo was associated with lower T2D risk (HR 0.86 [95%CI 0.75-0.98]) compared to  
65 Right-No-Chemo.

66 For all six groups, an increased level of BMI resulted in a nearly twofold increased risk of  
67 developing T2D

68 **Conclusion**

69 This study suggests postoperative T2D screening should be prioritized in CRC survivors with  
70 overweight/obesity regardless of type of colorectal cancer treatment applied.

71 **Funding**

72 The Novo Nordisk Foundation (*NNF17SA0031406*); TrygFonden (101390; 20045; 125132).

73 **Introduction**

74 Colorectal cancer (CRC) is the third most common cancer worldwide,<sup>1</sup> and the incidence rate is  
75 still increasing.<sup>2</sup> The same applies to the global incidence rate of type 2 diabetes (T2D). The  
76 association between CRC and T2D is well-established, as patients with T2D have approximately  
77 30% increased risk of developing CRC,<sup>3</sup> and T2D is known to negatively influence the prognosis of  
78 CRC.<sup>4</sup> Furthermore, some studies even show an increased T2D risk in CRC survivors.<sup>5,6</sup>

79 Fortunately, survival after a CRC diagnosis is steadily improving due to early detection, diagnostic  
80 precision, and more advanced cancer treatment; and today, more than 70% of non-metastatic CRC  
81 patients are alive after 5 years.<sup>7</sup> Accordingly, it becomes increasingly important to identify CRC  
82 patients at risk of developing long-term health problems like T2D in order to initiate preventive  
83 strategies or treatment.<sup>6</sup> The underlying mechanisms behind the increased T2D risk in CRC  
84 survivors are poorly understood. However, shared life-style related risk factors such as obesity,  
85 physical inactivity, and unhealthy diet may play a role.<sup>8-10</sup>

86 Another explanation may be treatment-induced hyperglycemia. Prior studies showed that treatment  
87 with adjuvant chemotherapy can induce hyperglycemia and development of T2D in CRC patients.  
88<sup>6,11,12</sup> Moreover, glucocorticoid, administered to alleviate side effects of chemotherapy, may impair  
89 glucose homeostasis and thus increase the risk of T2D.<sup>13,14</sup> In addition to the drug-induced  
90 metabolic disturbances, a recent study revealed that the type of CRC surgery *per se* is associated  
91 with diverging risk of T2D.<sup>15</sup> A previous nationwide Danish study revealed that patients, who had  
92 undergone left-sided colon resection for CRC and other colonic illnesses had an increased risk of  
93 developing T2D, whereas this risk was unaltered in patients who had undergone right-sided colonic  
94 resections compared with a control group.<sup>15</sup> However, this study lacks essential information on the  
95 role of potential modifying factors like BMI, treatment with chemotherapy etc. Along the same line,  
96 in a population of non-CRC patients, Lee et al. published that patients who had undergone right-  
97 sided or transversal colonic resections had a reduced risk of developing T2D compared with a  
98 matched non-colectomy control group.<sup>16</sup> These findings raise an intriguing question of whether the  
99 risk of developing T2D in CRC survivors may be casually affected by the type of CRC surgery.  
100 Possible explanations of this side-specific risk modification include removal of different  
101 enteroendocrine cell types resulting in gut changes that is important for insulin secretion and action  
102 and for appetite regulation as well as changes in the microbiome, but causality remains to be  
103 investigated further.<sup>17-19</sup>

105 In the present study, we tested the hypothesis whether different types of surgical cancer resection  
106 and oncological treatment have an impact on risk of developing diabetes in CRC survivors. For this  
107 purpose, we used a nationwide register to compare the frequency of diabetes development in CRC  
108 patients who had undergone right-sided colectomy, left-sided colectomy or rectal resection with and  
109 without chemotherapy, when adjusting for potential modifying factors like BMI etc.

110

## 111 **Methods and material**

### 112 **Study population**

113 The study was based on information from Danish nationwide health registers. All data are recorded  
114 with reference to a civil registration number, which is a unique personal identification number  
115 assigned to all Danish residents. This number permits accurate linkage of recorded information at  
116 the personal level.<sup>20</sup>

117

118 The study population was identified through the Danish Colorectal Cancer Group (DCCG)  
119 database, which contains prospectively collected and validated data on all patients with CRC since  
120 2001, including data on patient's characteristics, diagnostics and treatment.<sup>21</sup> The degree of patient  
121 inclusion in the database is high (>95%) and thus adequately represents the population of Danish  
122 CRC patients undergoing anti-cancer resections.<sup>21</sup>

123

124 We included all CRC cancer patients undergoing cancer surgery between 1<sup>st</sup> of May 2001 until 31<sup>st</sup>  
125 of December 2018 (Figure 1). Patients with unspecified surgery or total colectomy were excluded  
126 as these procedures are not standard treatment for CRC. Additionally, individuals diagnosed with  
127 Type 1 diabetes (T1D) either before or after surgery were excluded, along with those diagnosed  
128 with T2D preoperatively or within the first 2 weeks postoperatively, as the last group probably  
129 represents patients with preoperatively unknown pre-existing prediabetes or diabetes.

130 <sup>22</sup>

### 131 **Exposure**

132 Patients were subdivided into six groups according to the surgical procedure and whether the  
133 patients had received chemotherapy or not. The group "right-sided colonic resection" (Right)  
134 included patients with cancer in caecum, ascending colon, or the oral part of colon transversum, the  
135 group "left-sided colonic resection" (Left) included patients with cancer in the anal part of colon  
136 transversum, descending colon, and sigmoid colon, and the group "rectal resection" (Rectal)

137 included patients with rectal cancer. Information regarding chemotherapy was limited to whether  
138 the patient had received chemotherapy (Chemo) or not (No-Chemo).

139 Based on the combination of surgical procedures and chemotherapy, the study population was  
140 divided into six groups: Right-No-Chemo, Right-Chemo, Left-No-Chemo, Left-Chemo, Rectal-No-  
141 Chemo, Rectal-Chemo.

142 Radiation therapy is only part of standard treatment for rectal cancer, and therefore this oncological  
143 modality was restricted to Rectal patients (Rectal-No-Radiation vs. Rectal-Radiation).

144 Finally, a sub analysis was made comparing all colonic resected patients (All Colon) with all rectal  
145 resected (All Rectal)

146

### 147 **Outcome**

148 The primary outcome was first-time diagnosis of T2D after different types of CRC cancer surgery  
149 and chemotherapy. Patients were followed from date of surgery until time to T2D diagnosis,  
150 emigration, death, or the end of follow up (31<sup>st</sup> of December 2018), whichever came first.

151 Individuals with T2D were identified from data in the Danish National Patient Register (comprising  
152 information on diagnoses during all hospital contacts in Denmark), the National Prescription  
153 Registry (comprising information on all prescriptions filled at any pharmacy in Denmark), and the  
154 Danish National Health Service Register (comprising information on podiatrist services) as  
155 described by Carstensen et al.<sup>22</sup> Diabetes is defined as the second occurrence of any event across  
156 three types of inclusion events: 1) Diabetes diagnosed during hospitalisation 2) diabetes-specific  
157 services received at podiatrist, 3) purchases of glucose lowering drugs. Thus, if a patient developed  
158 transient T2D during chemotherapy treatment, it will only be an inclusion event if they purchase of  
159 glucose lowering drugs. Individuals were classified as having T1D if they had received  
160 prescriptions for insulin combined with a diagnosis of type 1 from a medical hospital department.

161 Otherwise, diabetes was classified as type 2.<sup>23</sup>

162

163

164

165

166

## 167 **Statistical analysis**

168 Descriptive data was presented as means with standard deviations (SD) for continuous variables and  
169 proportions (n, %) for categorical variables. Crude incidence rates (number of T2D diagnoses by  
170 person-time at risk) were calculated for the six groups (type of surgery ± chemo), and characterised  
171 by preoperative variables (sex, age, body mass index (BMI), smoking, alcohol status, American  
172 Society of Anesthesiologists physical status classification score (ASA), and treatment with  
173 radiotherapy in Rectal cancer patients). Unadjusted and adjusted Cox regression analyses were used  
174 to calculate hazard ratios (HRs) for developing T2D after different types of surgery with and  
175 without chemotherapy (using Right-No-Chemo as a reference group), after radiation therapy among  
176 Rectal resected (using Rectal-No-Radiation as reference), and after overall type of surgery (All  
177 Colon (ref) vs All Rectal). The adjusted analyses were performed stepwise by first adjusting for  
178 year of surgery, age at surgery, sex and BMI (Model 1), then further adjusting ASA, smoking and  
179 alcohol consumption (Model 2a), and lastly, further adjusting for chemotherapy (Model 2b) in the  
180 analyses on radiation therapy and overall type of surgery

181

182 Finally, the impact of BMI on the risk of developing of T2D was investigated within each of the six  
183 groups. BMI was categorized into 4 subgroups (18.5-24.9, 25-29.9, 30-34.9 and 35-39.9), and  
184 underweight (BMI<18.5) or severely obese (BMI ≥ 40) subjects were excluded from these analyses  
185 due to low numbers. For each group (type of surgery ± chemotherapy), the HR for developing T2D  
186 depending on BMI subgroups was calculated by using Cox regression analysis adjusted for age,  
187 sex, year of surgery, and ASA score using normal weight (BMI:18.5-24.9) as the reference group.

188 A sensitivity analyses was performed restricting the inclusion period of surgery patients from 2001-  
189 2018 to 2010-2018, as baseline information was complete from 2010.

190 All analyzes were conducted using STATA version 16 (STATA Corp., College Station, Tex.,  
191 USA). P-value of P<0.05 was considered statistically significant. Results were presented with 95%  
192 confidence interval (CI) when relevant.

193

## 194 **Results**

### 195 **Baseline characteristics**

196 A total of 46,373 CRC patients without preoperatively recorded diabetes were found eligible for the  
197 study (Figure 1) and were divided into six groups: 10,566 Right-No-Chemo (23%), 4,645 Right-

198 Chemo (10%), 10,151 Left-No-Chemo (22%), 5,257 Left-Chemo (11%), 9,618 Rectal-No-Chemo  
199 (21%) and 6,136 Rectal-Chemo (13%).

200 Compared with the Right, the Left and Rectal groups were younger, more often men, and less often  
201 classified as ASA>II (Table 1). Those that had received chemotherapy were generally younger, less  
202 often classified as ASA>II and as expected more often stage III/IV cancers than No-Chemo.

203

#### 204 **Incidence rates of diabetes**

205 During the 245,466 person-years of follow up, 2,556 cases of T2D were diagnosed (10.4 per 1000  
206 person-years) (Table 2) and the mean time to onset of T2D post-surgery spanned from 4.1-4.7 years  
207 across the subgroups. The incidence rate (IR) of T2D was almost similar between the six groups  
208 with the highest IR observed in the Left-No-Chemo group (IR 11.3 (95%CI: 10.4-12.2) per 1,000  
209 person-years), and the lowest IR observed in the Rectal-No-Chemo group (IR 9.6 (95%CI: 8.8-  
210 10.4) per 1,000 person-years). Across all groups, the T2D IR was consistently higher in males than  
211 in females, in patients with BMI  $\geq 25$  compared with BMI of 18.5-24.9, and in ASA > I compared  
212 with ASA score I (Table 2).

213

#### 214 **Risk of developing T2D after different types of colorectal cancer surgery with and without** 215 **chemotherapy**

216 When compared with the Right-No-Chemo group, the other groups had similar and non-significant  
217 unadjusted hazard ratio (HR) of developing T2D (Table 3). In the adjusted analysis Rectal-No-  
218 Chemo was associated with a lower risk of T2D (HR 0.86 [95%CI 0.75-0.98]) compared with  
219 Right-No-Chemo. In the sub analysis comparing All Colon resected with All Rectal resected, the  
220 unadjusted and adjusted HR for developing T2D were significant lower for Rectal resected.  
221 Moreover, adjusting for cancer stage did not affect the results (Supplementary table 1).

222

#### 223 **Risk of developing T2D after radiation therapy among rectal resected patients**

224 Radiation therapy in the rectal resected groups had no impact on the incidence rate of (Table 2), and  
225 the unadjusted/adjusted HR of developing T2D was non-significant when comparing Rectal-No-  
226 Radiation patients with Rectal-Radiation patients (Table 3).

227



## 228 **The impact of BMI on development of T2D**

229 BMI had a strong association with T2D regardless of surgical resection and treatment with  
230 chemotherapy (Figure 2). The risk of developing T2D increased near twofold every time the BMI  
231 group increased one level, for example in the Right-No-Chemo group: HR 2.13 in BMI 25-30, HR  
232 3.63 in BMI 30-35, HR 8.01 in BMI 35-40, compared with the reference BMI of 18.5-25. A similar  
233 pattern was observed within each of the other five groups, although a less pronounced impact of  
234 BMI was observed in the Left-No-Chemo group: HR 1.85 in 25-30, 2.93 in 30-35, 4.21 in 35-40  
235 BMI group.

236

## 237 **Discussion**

238 This national cohort study demonstrated an IR of developing T2D after CRC surgery similar to  
239 previous studies.<sup>5,11</sup> Comparing resection types, rectal cancer resected patients had a slightly lower  
240 risk of developing T2D when compared to colon cancer resected patients. Treatment with  
241 chemotherapy had no impact on T2D risk in any of the resection groups, and radiation therapy did  
242 not affect T2D risk either.

243 Within each of the six groups (different types of surgery with and without chemotherapy), BMI was  
244 strongly associated to developing T2D, the risk increased almost twofold every time the BMI group  
245 increased one level.

246 Only few studies have examined the risk of developing T2D after different kinds of colonic- and  
247 rectal surgical procedures, and in contrast to the present study the following studies were not able to  
248 adjust for several confounders incl. preoperative BMI. Jensen et al. found a higher risk of T2D after  
249 the left-sided compared with the right-sided colonic resections, but, in contrast to the current study,  
250 patients operated for both non-malignant as well as malignant diseases were included.<sup>15</sup> In support  
251 of side-specific effect of colonic resections, Wu et al. investigated a population of non-CRC  
252 patients and showed that right-sided and transversal colonic resections were associated with a  
253 reduced risk of T2D development compared with patients without colectomy.<sup>16</sup> In contrast to both  
254 the abovementioned studies the most recent epidemiological study found an increased T2D risk  
255 after colectomy compared with small bowel resection in non-cancer patients, but when stratifying  
256 by resection type, they found no difference in T2D risk.<sup>24</sup>

257 In Denmark, the overall T2D prevalence is 6.9%<sup>25</sup>, lower than the global average in 2021 (10.5%)  
258 and also falls below the estimate of high-income countries (11.1%).<sup>26</sup> Similarly, the obesity rate of  
259 20% aligns with other Scandinavian countries and is below that of most high-income nations.<sup>27</sup>



260

261 Obesity is one of the predominant factors in the development of T2D<sup>28-30</sup>, and the linear increase in  
262 new onset T2D with increased BMI reported in this study is well described in the literature.<sup>31</sup> It is  
263 important to emphasize that only pre-operative BMI was included in the adjustments as post-  
264 surgery BMI information was not available and accordingly, weight trajectories after surgery could  
265 not be included in the analyses. It's still unknown how body weight and body composition changes  
266 after different types of CRC resection, and thus it is not clear whether changes in weight in any  
267 groups play a role in diabetes development.

268

269 Like our findings, Jensen et al. and Wu et al. found a tendency towards a decreased risk of T2D  
270 after rectal resection, although these findings were not statistically significant in the previous  
271 studies.<sup>15,16</sup> Further studies are needed to elucidate the potential mechanism behind this finding.

272 We found no impact of treatment with chemotherapy on T2D risk, which was a bit surprising. Prior  
273 studies indicated that treatment with chemotherapy may induce hyperglycemia, and especially the  
274 combined use of chemotherapy and glucocorticoid, administered to alleviate side-effects of  
275 chemotherapy, may have synergistic effects on later diabetes risk.<sup>32</sup>

276 In the study period of the present study, different types of chemotherapy have been part of the  
277 standard treatment of colon and rectum cancer respectively, and knowledge regarding the specific  
278 effects of each drug on glucose homeostasis is sparse.<sup>33</sup> In most cases CRC patients included in the  
279 study, will however have been treated with the chemotherapy 5-Flourouracil.<sup>12</sup> In a recent study a  
280 significant increase in glycemic variability, a precursor of T2D development, was found in non-  
281 diabetic early-stage colon cancer patients during 5-Flourouracil and Capecitabine chemotherapy  
282 treatment.<sup>34</sup> Moreover, Feng et al. showed a 10% increased risk of developing T2D in CRC  
283 patients during and after treatment with adjuvant 5- Flourouracil. They argued that 5-Flourouracil  
284 could induce toxicity in B-cells leading to hyperglycaemia.<sup>12</sup> Similarly, Lee et al revealed an  
285 impairment in glucose homeostasis in both breast cancer and CRC patients treated with  
286 chemotherapy and glucocorticoid following treatment.<sup>13</sup> Nonetheless 65% of the newly diagnosed  
287 T2D cases remitted 6 months after discontinuation of chemotherapy, suggesting that chemotherapy  
288 is a reversible diabetogenic factor.<sup>13</sup> Thus, in summary, treatment with chemotherapy may  
289 primarily induce transient effects on glucose homeostasis in CRC patients. In contrast to the lack of  
290 influence of chemotherapy treatment, it was not surprising that radiation therapy had no impact on  
291 diabetes risk in our study.

292

293 Due to the strong negative prognostic effects of comorbidity with T2D on CRC outcomes,  
294 identifying CRC patients at increased risk of developing T2D is of great clinical importance. Our  
295 study did not support a role of cancer surgery with left-sided colonic resection or treatment with  
296 chemotherapy in T2D development in CRC survivors. However, in line with existing literature we  
297 found BMI to be strongly associated with T2D development.

298

299 A core strength of the present study is the use of a nationwide database, allowing inclusion of large  
300 numbers of CRC patients treated with different types of CRC resections, providing valid real-life  
301 data regarding with close to complete coverage and long-term follow-up and a register-based  
302 approach to identify individuals with T2D. We were able to adjust for several confounders such as  
303 BMI, alcohol consumption and smoking, which has been a limitation in previous studies.<sup>15,16</sup>

304 The limitation of the present study includes that information on BMI and other risk factors for  
305 developing T2D were only available preoperatively, eliminating the possibility of exploring an  
306 impact of BMI trajectories after cancer treatment until the T2D diagnosis.<sup>35</sup> Secondly, information  
307 on dose, length of treatment and type of chemotherapy were not available. Thirdly, information on  
308 physical activity, diet, medication, and comorbidities, apart from the ASA score, were not available.  
309 In addition, our findings are limited by the register-based data collection method. Clinical well-  
310 designed mechanistic investigations are warranted to establish whether left-sided CRC resection *per*  
311 *se* drives metabolic alterations leading to an increased risk of T2D.

312

313 In summary, we report a slightly increased risk of developing T2D after CRC treatment with  
314 colonic resection compared with rectal resection, whereas chemotherapy had no impact on new  
315 onset T2D. Within each surgical subgroup, BMI at time of surgery was strongly associated to  
316 developing T2D. This study suggests that postoperative diabetes screening should be prioritized in  
317 CRC survivors with overweight/obesity regardless of type of colorectal cancer treatment applied.

318

### 319 **Acknowledgement**

320 The authors thank the DCCG for access to data and Danish Cancer Society for support.

321

322 **Funding**

323 This work was supported by the Danish Diabetes Association and the Danish Diabetes Academy,  
324 which is funded by the Novo Nordisk Foundation, grant number *NNF17SA0031406*.

325 The Centre for Physical Activity Research (CFAS) is supported by TrygFonden (grants ID 101390,  
326 ID 20045, and ID 125132).

327

328 **Ethics approval**

329 According to Danish law and the Committee on Health Research Ethics in the Central Denmark  
330 Region, the study required no ethical approval because it was based on secondary use of register  
331 data for research purposes. This committee also waived patient consent for the use of register data.

332 The study was approved by the Central Region Denmark (file no. 1-16-02-304-19).

333

334 **Patient consent for publication**

335 Not applicable

336

337 **Contributors**

338 Conceptualization, TL and LLL. Methodology, TL, LLL, CK, TIAS, MSS and JFC. Access to and  
339 verified the raw data and formal analysis TL and SBG. Resources, TL, LLL. Writing - Original  
340 draft CK, TL, LLL, MSS and SM. Writing – Review and editing, all authors contributed.

341 All authors approved the final version for publication, and LLL had final responsibility for the  
342 decision to submit.

343

344 **Declaration of interests**

345 The authors disclose no conflicts.

346

347 **Data sharing**

348 Anonymized data will be made available upon reasonable request for academic use and within the  
349 limitations of the informed consent. Requests should be made to last author tinlaurb@rm.dk. Due to  
350 the Danish law it is not possible to make national health registers available, but on request we  
351 would like to collaborate and discuss reasonable access to data.

352

353

354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388

389

390

391 **Reference**

- 392 1. Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality:  
393 projections to the year 2035. *Int J Cancer*. 2019;144(12):2992-3000. doi:10.1002/ijc.32055
- 394 2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and  
395 trends in colorectal cancer incidence and mortality. *Gut*. 2017;66(4):683-691.  
396 doi:10.1136/gutjnl-2015-310912
- 397 3. González N, Prieto I, del Puerto-Nevado L, et al. *2017 Update on the Relationship between*  
398 *Diabetes and Colorectal Cancer: Epidemiology, Potential Molecular Mechanisms and*  
399 *Therapeutic Implications*. Vol 8.; 2017. [www.impactjournals.com/oncotarget](http://www.impactjournals.com/oncotarget)
- 400 4. Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and  
401 colorectal cancer prognosis: A meta-analysis. *Dis Colon Rectum*. 2013;56(11):1304-1319.  
402 doi:10.1097/DCR.0b013e3182a479f9
- 403 5. Singh S, Earle CC, Bae SJ, et al. Incidence of Diabetes in Colorectal Cancer Survivors. *J*  
404 *Natl Cancer Inst*. 2016;108(6). doi:10.1093/jnci/djv402
- 405 6. Xiao Y, Wang H, Tang Y, et al. Increased risk of diabetes in cancer survivors: a pooled  
406 analysis of 13 population-based cohort studies. *ESMO Open*. 2021;6(4).  
407 doi:10.1016/j.esmoop.2021.100218
- 408 7. Colorectal D, Nordcan 2019. *5-Year Age-Standardised Relative Survival (%), Males and*  
409 *Females*. Accessed September 12, 2022.  
410 "https://nordcan.iarc.fr/en/dataviz/survival?cancers=520&set\_scale=0&sexes=1\_2&populati  
411 ons=208" has been copied into your clipboard
- 412 8. Nano J, Dhana K, Asllanaj E, et al. Trajectories of BMI Before Diagnosis of Type 2  
413 Diabetes: The Rotterdam Study. *Obesity*. 2020;28(6):1149-1156. doi:10.1002/oby.22802
- 414 9. Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes.  
415 *Translational Research*. 2017;184:101-107. doi:10.1016/j.trsl.2017.02.004
- 416 10. Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer-Pathophysiology and  
417 Clinical Implications. *Endocr Rev*. 2020;41(1). doi:10.1210/endrev/bnz014
- 418 11. Jo A, Scarton L, O'Neal LTJ, et al. New onset of type 2 diabetes as a complication after  
419 cancer diagnosis: A systematic review. *Cancer Med*. 2021;10(2):439-446.  
420 doi:10.1002/cam4.3666
- 421 12. Feng JP, Yuan XL, Li M, et al. Secondary diabetes associated with 5-fluorouracil-based  
422 chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a  
423 single-centre cohort study. *Colorectal Disease*. 2013;15(1):27-33. doi:10.1111/j.1463-  
424 1318.2012.03097.x
- 425 13. Lee EK, Koo B, Hwangbo Y, et al. Incidence and disease course of new-onset diabetes  
426 mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective  
427 multicenter cohort study. *Diabetes Res Clin Pract*. 2021;174.  
428 doi:10.1016/j.diabres.2021.108751
- 429 14. Jeong Y, Han HS, Lee HD, et al. A pilot study evaluating steroid-induced diabetes after  
430 antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. *Cancer Res*  
431 *Treat*. 2016;48(4):1429-1437. doi:10.4143/crt.2015.464
- 432 15. Jensen AB, Sørensen TI, Pedersen O, Jess T, Brunak S, Allin KH. Increase in clinically  
433 recorded type 2 diabetes after colectomy. Published online 2018.  
434 doi:10.7554/eLife.37420.001

- 435 16. Wu CC, Lee CH, Hsu TW, et al. Is colectomy associated with the risk of type 2 diabetes in  
436 patients without colorectal cancer? A population-based cohort study. *J Clin Med*.  
437 2021;10(22). doi:10.3390/jcm10225313
- 438 17. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis.  
439 *Diabetes Care*. 2016;39(6):884-892. doi:10.2337/dc16-0351
- 440 18. Lin XH, Jiang JK, Luo JC, et al. The long term microbiota and metabolic status in patients  
441 with colorectal cancer after curative colon surgery. *PLoS One*. 2019;14(6).  
442 doi:10.1371/journal.pone.0218436
- 443 19. Palnæs Hansen C, Andreasen JJ, Holst JJ. The release of gastric inhibitory peptide, glucagon-  
444 like peptide-I, and insulin after oral glucose test in colectomized subjects. *Scand J*  
445 *Gastroenterol*. 1997;32(5):473-477. doi:10.3109/00365529709025084
- 446 20. Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB, Med Bull D. *The Danish Civil*  
447 *Registration System A Cohort of Eight Million Persons*.
- 448 21. Klein MF, Gögenur I, Ingeholm P, et al. Validation of the Danish Colorectal Cancer Group  
449 (DCCG.dk) database – on behalf of the Danish Colorectal Cancer Group. *Colorectal*  
450 *Disease*. Published online 2020. doi:10.1111/codi.15352
- 451 22. Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes  
452 register. *Scand J Public Health*. 2011;39(7):58-61. doi:10.1177/1403494811404278
- 453 23. Isaksen AA, Sandbæk A, Bjerg L. Validation of Register-Based Diabetes Classifiers in  
454 Danish Data. *Clin Epidemiol*. 2023;15:569-581. doi:10.2147/CLEP.S407019
- 455 24. Allin KH, Agrawal M, Iversen AT, Antonsen J, Villumsen M, Jess T. The Risk of Type 2  
456 Diabetes in Patients With Inflammatory Bowel Disease After Bowel Resections: A  
457 Nationwide Cohort Study. *Gastro Hep Advances*. 2022;1(5):777-784.  
458 doi:10.1016/j.gastha.2022.06.007
- 459 25. Diabetesforeningen. Nøgletal om diabetespopulation Type 2 2. Kvartal 2023.  
460 <https://www.diabetestal.nu>. Published November 17, 2023. Accessed December 20, 2023.  
461 <https://www.diabetestal.nu>
- 462 26. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level  
463 diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*.  
464 2022;183. doi:10.1016/j.diabres.2021.109119
- 465 27. Hannah Ritchie, Max Roser. Obesity. Our World in Data. Published September 11, 2017.  
466 Accessed December 20, 2023. <https://ourworldindata.org/obesity>
- 467 28. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. *Comparison of Abdominal Adiposity*  
468 *and Overall Obesity in Predicting Risk of Type 2 Diabetes among Men 1-3.*; 2005.  
469 <https://academic.oup.com/ajcn/article/81/3/555/4648892>
- 470 29. Hu Y, Bhupathiraju SN, de Koning L, Hu FB. Duration of obesity and overweight and risk of  
471 type 2 diabetes among US women. *Obesity*. 2014;22(10):2267-2273. doi:10.1002/oby.20851
- 472 30. Lee DH, Keum NN, Hu FB, et al. Comparison of the association of predicted fat mass, body  
473 mass index, and other obesity indicators with type 2 diabetes risk: two large prospective  
474 studies in US men and women. *Eur J Epidemiol*. 2018;33(11):1113-1123.  
475 doi:10.1007/s10654-018-0433-5
- 476 31. Easson Karin A, Jon E, Martin A, et al. Body mass index in adolescence, risk of type 2  
477 diabetes and associated complications: A nationwide cohort study of men. Published online  
478 2022. doi:10.1016/j
- 479 32. Hwangbo Y, Kang D, Kang M, et al. Incidence of diabetes after cancer development a  
480 Korean national cohort study. *JAMA Oncol*. 2018;4(8):1099-1105.  
481 doi:10.1001/jamaoncol.2018.1684

- 482 33. Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EGE, Jalving M. Cancer-drug  
483 induced insulin resistance: Innocent bystander or unusual suspect. *Cancer Treat Rev.*  
484 2015;41(4):376-384. doi:10.1016/j.ctrv.2015.02.007
- 485 34. Mandolfo NR, Berger AM, Struwe LA, et al. Glycemic Variability in Patients With Stage II–  
486 III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy. *Oncol Nurs Forum.*  
487 2022;49(6):571-584. doi:10.1188/22.ONF.571-584
- 488 35. Winkels RM, Snetselaar T, Adriaans A, et al. Changes in body weight in patients with  
489 colorectal cancer treated with surgery and adjuvant chemotherapy: An observational study.  
490 *Cancer Treat Res Commun.* 2016;9:111-115. doi:10.1016/j.ctarc.2016.09.002  
491  
492  
493



494

<b>Table 1. Baseline characteristics</b>						
	Right-sided resection (Right) (N=15,211)		Left-sided resection (Left) (N=15,408)		Rectum resection (Rectal) (N=15,754)	
	<i>Right-No-Chemo</i>	<i>Right-Chemo</i>	<i>Left-No-Chemo</i>	<i>Left-Chemo</i>	<i>Rectal-No-Chemo</i>	<i>Rectal-Chemo</i>
<b>All patients, n (%)</b>	10,566 (23%)	4,645 (10%)	10,151 (22%)	5,257 (11%)	9,618 (21%)	6,136 (13%)
<b>Sex, n (%)</b>						
Male	4,338 (41%)	2,126 (46%)	5,450 (54%)	2,834 (54%)	5,743 (60%)	3,745 (61%)
Female	6,228 (59%)	2,519 (54%)	4,701 (46%)	2,423 (46%)	3,875 (40%)	2,391 (39%)
<b>Age, year, mean (SD)</b>	75.2 (10.0)	66.9 (10.1)	72.1 (10.7)	64.8 (10.1)	70.0 (10.7)	64.3 (10.1)
<b>BMI, mean (SD)</b>	25.0 (4.7)	25.4 (4.7)	25.7 (4.6)	25.8 (4.5)	25.6 (4.4)	25.6 (4.4)
<b>BMI subgroups</b>						
<18.5	482 (4.6%)	114 (2.5%)	287 (2.8%)	97 (1.8%)	225 (2.3%)	143 (2.3%)
18.5-24.9	4,183 (40%)	1,907 (41%)	3,638 (36%)	2,004 (38%)	3,693 (38%)	2,570 (42%)
25-29.9	2,671 (25%)	1,347 (29%)	2,945 (29%)	1,641 (31%)	3,021 (31%)	1,993 (32%)
30-34.9	814 (7.7%)	404 (8.7%)	961 (9%)	545 (10%)	889 (9.2%)	611 (10%)
35-39.9	194 (1.8%)	90 (1.9%)	214 (2.1%)	135 (2.6%)	171 (1.8%)	132 (2.2%)
>40	62 (0.6%)	34 (0.7%)	69 (0.7%)	39 (0.7%)	60 (0.6%)	30 (0.5%)
Missing	2,160 (20%)	749 (16%)	2,037 (20%)	796 (15%)	1,559 (16%)	657 (11%)
<b>Smoking, n (%)</b>						
Never	3,132 (30%)	1,533 (33%)	3,030 (30%)	1,804 (34%)	2,828 (29%)	2,014 (33%)
Current	1,671 (16%)	791 (17%)	1,486 (15%)	821 (16%)	1,679 (17%)	1,305 (21%)
Former	3,376 (32%)	1,465 (32%)	3,415 (34%)	1,700 (32%)	3,421 (36%)	2,021 (33%)
Missing	2,387 (22%)	856 (18%)	2,220 (21%)	932 (18%)	1,690 (18%)	796 (13%)
<b>Alcohol<sup>a</sup>, n (%)</b>						
1-14	4,819 (46%)	2,342 (51%)	4,803 (47%)	2,771 (53%)	4,886 (51%)	3,399 (55%)
14-21	478 (5%)	254 (5%)	618 (6%)	333 (6%)	711 (7%)	494 (8%)
>21	433 (4%)	256 (6%)	593 (6%)	323 (6%)	671 (7%)	412 (7%)
None	2,269 (21%)	889 (19%)	1,722 (17%)	872 (17%)	1,446 (15%)	1,006 (16%)
Missing	2,567 (24%)	895 (19%)	2,415 (24%)	958 (18%)	1,904 (20%)	825 (13%)
<b>ASA score<sup>b</sup>, n (%)</b>						
Healthy (=I)	1,633 (15%)	1,331 (29%)	2,185 (22%)	1,735 (33%)	2,541 (26%)	2,082 (34%)
Mild (=II)	5,457 (52%)	2,596 (56%)	5,299 (51%)	2,857 (54%)	5,265 (55%)	3,415 (56%)
Sick (=>II)	3,160 (30%)	613 (13%)	2,442 (24%)	548 (11%)	1,653 (17%)	557 (9%)
Missing	316 (3%)	105 (2%)	295 (3%)	117 (2%)	159 (2%)	82 (1%)
<b>Screening detected tumor, n (%)</b>	770 (7%)	299 (6%)	1,077 (11%)	457 (9%)	664 (7%)	394 (6%)
<b>UICC stage<sup>c</sup>, n (%)</b>						
I/II	7,002 (66%)	674 (15%)	7,339 (72%)	745 (14%)	5,940 (62%)	420 (7%)
III/IV	3,330 (32%)	3,504 (75%)	2,506 (25%)	3,989 (76%)	2,246 (23%)	2,471 (40%)
Unknown	234 (2%)	467 (10%)	306 (3%)	523 (10%)	1,432 (15%)	3,245 (53%)
<b>Radiation, n (%)</b>	.	.	.	.	1,157 (12%)	2,983 (49%)

Chemo: Chemotherapy  
<sup>a</sup> Alcohol items per week  
<sup>b</sup> The American Society of Anesthesiologist score: I: Healthy, but with CRC, III: Mild systemic disease without substantial functional limitations, >II: Severe systemic disease, includes ASA stage III, IV, V, VI  
<sup>c</sup> UICC stage, Union of International Cancer Control, Stage I: T1 or T2, Stage II: T3 or T4, Stage III: N1 or N2, Stage IV: Disseminated disease at time of diagnosis

495

496

497

498  
499  
500

501

**Table 2. Absolute incidence rates of type 2 diabetes (T2D) per 1000 person-years (95% CI) among colorectal cancer patients treated with different types of colorectal cancer surgery with and without chemotherapy.**

	Right-sided resection (Right) (N=15,211)		Left-sided resection (Left) (N=15,408)		Rectum resection (Rectal) (N=15,754)	
	<i>Right-No-Chemo</i>	<i>Right-Chemo</i>	<i>Left-No-Chemo</i>	<i>Left-Chemo</i>	<i>Rectal-No-Chemo</i>	<i>Rectal-Chemo</i>
<b>All patients, n</b>	10,566	4,645	10,151	5,257	9,618	6,136
<b>T2D development</b>						
Numbers	495	235	609	323	560	334
Mean time, year (SD)	4.1 (3.4)	4.1 (3.6)	4.1 (3.5)	4.4 (3.6)	4.7 (3.7)	4.3 (3.5)
<b>Person-years</b>	48,039	22,317	53,935	29,301	58,448	33,422
<b>Incidence rates</b>	10.3 (9.4-11.2)	10.5 (9.3-12.0)	11.3 (10.4-12.2)	11.0 (9.9-12.3)	9.6 (8.8-10.4)	10.0 (9.0-11.1)
<b>Sex</b>						
Male	13 (11-15)	14 (12-16)	14 (12-15)	14 (12-16)	11 (10-12)	12 (11-14)
Female	9 (8-10)	8 (7-10)	9 (8-10)	8 (7-10)	8 (7-9)	7 (6-8)
<b>Age</b>						
<50	3 (1-8)	6 (3-11)	7 (5-12)	8 (5-12)	5 (3-8)	6 (4-10)
50-64.9	12 (10-14)	13 (11-16)	11 (9-12)	10 (8-12)	10 (8-12)	10 (9-12)
65-74.9	12 (11-14)	11 (9-14)	12 (11-14)	14 (12-17)	14 (12-17)	11 (10-13)
≥75	9 (8-10)	6 (4-9)	11 (10-13)	8 (6-12)	8 (6-12)	8 (5-11)
<b>BMI subgroups</b>						
18.5-24.9	6 (5-7)	5 (4-7)	6 (5-8)	4 (3-5)	4 (4-5)	4 (3-6)
25-29.9	13 (11-16)	11 (9-14)	13 (11-15)	12 (10-15)	11 (9-12)	12 (10-14)
30-34.9	23 (18-28)	30 (23-40)	21 (17-25)	24 (19-30)	25 (21-30)	24 (19-30)
35-39.9	51 (38-70)	53 (34-84)	32 (23-45)	34 (23-52)	30 (21-44)	31 (20-48)
Missing	7 (6-9)	9 (6-12)	11 (9-12)	12 (10-16)	9 (8-12)	10 (8-14)
<b>Smoking</b>						
Never	9 (8-11)	11 (9-14)	9 (8-11)	8 (7-10)	8 (7-10)	9 (7-11)
Current	13 (10-15)	9 (7-13)	11 (9-14)	12 (10-16)	10 (8-12)	10 (7-12)
Former	11 (10-13)	12 (10-15)	13 (11-15)	13 (11-15)	11 (9-12)	11 (9-13)
Missing	8 (7-10)	9 (6-12)	11 (10-14)	12 (9-15)	9 (8-11)	11 (8-14)
<b>Alcohol<sup>a</sup></b>						
1-14	11 (9-12)	10 (8-12)	10 (9-12)	10 (9-12)	9 (8-10)	10 (8-11)
14-21	9 (6-14)	7 (3-14)	9 (6-13)	10 (7-16)	8 (6-11)	9 (6-14)
>21	10 (7-16)	16 (11-25)	14 (11-19)	12 (8-18)	11 (9-15)	13 (9-18)
None	12 (10-14)	14 (10-18)	13 (11-16)	12 (9-16)	13 (11-15)	10 (7-13)
Missing	9 (7-10)	10 (7-13)	12 (10-14)	12 (10-16)	10 (9-10)	10 (8-13)
<b>ASA score<sup>b</sup></b>						
Healthy (=I)	7 (6-9)	5 (3-7)	7 (6-9)	7 (5-9)	5 (4-6)	6 (4-7)
Mild (=II)	10 (9-12)	12 (11-15)	12 (11-13)	13 (11-15)	11 (10-12)	13 (11-14)
Sick (=>II)	14 (12-17)	17 (13-24)	17 (12-17)	18 (14-25)	15 (12-18)	12 (8-17)
Missing	6 (3-11)	15 (7-31)	13 (8-20)	11 (5-23)	9 (5-17)	10 (4-25)
<b>Radiation</b>						
Yes	.	.	.	.	11 (9-13)	11 (9-13)
No	.	.	.	.	9 (9-10)	10 (9-12)

Chemo: Chemotherapy

<sup>a</sup> Alcohol items per week

<sup>b</sup> The American Society of Anesthesiologist score: I: Healthy, but with CRC, III: Mild systemic disease without substantial functional limitations, >II: Severe systemic disease, includes ASA stage III, IV, V, VI

502

503

504

505

**Table 3. Likelihood of developing type 2 diabetes after different types of colorectal cancer surgery with and without oncological treatment, unadjusted and adjusted analysis**

	Unadjusted		Model 1		Model 2 <sup>(a/b)</sup>	
	HR (95% CI)	<i>p-value</i>	HR (95% CI)	<i>p-value</i>	HR (95% CI)	<i>p-value</i>
<b>Surgery and chemotherapy</b>						
Right-No-Chemo	ref					
Right-Chemo	1.02 (0.87;1.19)	0.799	0.99 (0.83;1.17)	0.880	1.01 (0.85;1.20) <sup>a</sup>	0.884
Left-No-Chemo	1.10 (0.98;1.24)	0.112	0.92 (0.81;1.05)	0.228	0.94 (0.82;1.07) <sup>a</sup>	0.333
Left-Chemo	1.07 (0.93;1.23)	0.339	0.93 (0.79;1.09)	0.366	0.97 (0.83;1.14) <sup>a</sup>	0.708
Rectal-No-Chemo	0.94 (0.83;1.06)	0.317	0.82 (0.72;0.94)	0.004	0.86 (0.75;0.98) <sup>a</sup>	0.028
Rectal-Chemo	0.96 (0.84;1.11)	0.610	0.84 (0.72;0.99)	0.031	0.89 (0.76;1.03) <sup>a</sup>	0.126
<b>Surgery and radiation therapy</b>						
Rectal-No-Radiation	ref					
Rectal-Radiation	1.07 (0.93;1.24)	0.336	0.98 (0.85;1.13)	0.804	0.97 (0.84;1.12) <sup>b</sup>	0.691
<b>Surgery</b>						
All Colon	ref					
All Rectal	0.90 (0.83;0.98)	0.013	0.87 (0.79;0.95)	0.002	0.89 (0.82;0.98) <sup>b</sup>	0.015

Right: Right-sided colonic resections; Left: Left-sided colonic resections; Rectal: Rectal resections  
 No-Chemo: No chemotherapy; Chemo: Chemotherapy  
 No-radiation: No radiotherapy; Radiation: Radiation therapy

All Colon: All right- and left-sided colonic resections with and without chemotherapy  
 All Rectal: All rectal resections with and without chemotherapy, and with and without radiation therapy

Model 1: adjusted for year of surgery, age at surgery, sex, BMI  
 Model 2a: adjusted like Model 1 and further adjusted for performance status before surgery assessed by American Society of Anesthesiologist physical scale, smoking and alcohol  
 Model 2b: adjusted like Model 2a and further adjusted for chemotherapy

506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521

**Supplementary table 1. Likelihood of developing type 2 diabetes after different types of colorectal cancer surgery with and without oncological treatment, adjusted for UICC alone and in Model 1 and Model 2**

	Adjusted for UICC		Model 1 + UICC		Model 2+UICC	
	HR (95% CI)	<i>p-value</i>	HR (95% CI)	<i>p-value</i>	HR (95% CI)	<i>p-value</i>
<b>Surgery and chemotherapy</b>						
Right-No-Chemo	ref					
Right-Chemo	0.98 (0.83;1.15)	0.788	0.93 (0.78;1.11)	0.441	0.97 (0.81;1.16)	0.731
Left-No-Chemo	1.11 (0.98;1.24)	0.097	0.93 (0.81;1.06)	0.269	0.94 (0.83;1.07)	0.374
Left-Chemo	1.03 (0.89;1.19)	0.730	0.88 (0.74;1.03)	0.120	0.93 (0.79;1.09)	0.373
Rectal-No-Chemo	0.93 (0.82;1.05)	0.225	0.81 (0.71;0.93)	0.002	0.85 (0.74;0.97)	0.018
Rectal-Chemo	0.89 (0.76;1.04)	0.139	0.76 (0.64;0.90)	0.002	0.82 (0.69;0.97)	0.022

Right: Right-sided colonic resections; Left: Left-sided colonic resections; Rectal: Rectal resections  
 No-Chemo: No chemotherapy; Chemo: Chemotherapy

All Colon: All right- and left-sided colonic resections with and without chemotherapy  
 All Rectal: All rectal resections with and without chemotherapy, and with and without radiation therapy

Model 1: adjusted for year of surgery, age at surgery, sex, BMI  
 Model 2: adjusted like Model 1 and further adjusted for performance status before surgery assessed by American Society of Anesthesiologist physical scale, smoking and alcohol

522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549


550 **Figure legends**

551 **Figure 1:** Flowchart of the study.

552

553 **Figure 2:** Likelihood of developing type 2 diabetes depending on BMI subgroups (using normal  
554 weight, BMI:18.5-25 as reference) after different types of colorectal cancer surgery with and  
555 without chemotherapy.






**Figure 1:** Flowchart of the study

T2D: New-onset of type 2 diabetes

Right: Right-sided colonic resections; Left: Left-sided colonic resections; Rectal: Rectal resections

No-chemo: No chemotherapy; Chemo: Chemotherapy

## Surgery, Chemotherapy and BMI



**Figure 2:** Likelihood of developing type 2 diabetes depending on BMI subgroups (using normal weight, BMI:18.5-25 as reference) after different types of colorectal cancer surgery with and without chemotherapy.

◊Hazard ratios were adjusted for age, sex, year of surgery and ASA score (performance status before surgery assessed by American Society of Anesthesiologist physical scale).